医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Samsung Bioepis Announces Results of Additional One-Year Follow-Up Study Comparing Event-Free Survival of SB3 Trastuzumab Biosimilar Candidate to Reference Trastuzumab by ADCC Activity
Samsung Bioepis Co., Ltd. today announced the results of an additional one-year follow-up study comparing event-free survival (EFS) of SB3, a biosimilar candidate referencing HERCEPTIN® 1 (trastuzumab), to reference trastuzumab (TRZ) by antibody-dependent cell-mediated cytotoxicity (ADCC) activity. ADCC is a key mechanism of action for trastuzumab. The study results are being presented at the 2018 San Antonio Breast Cancer Symposium® (SABCS) which is being held December 4-8, 2018 in San Antonio, Texas.… 続きを読む
2018年12月08日 PM11:10
2018年12月07日
Aptorum Group Limited Announces Pricing of Initial Public Offering
Aptorum Group Limited (“Aptorum”, or the “Company”), a Hong Kong based pharmaceutical company currently in the preclinical stage, dedicated to developing and commercializing therapeutic projects and diagnostic technologies to tackle unmet medical needs, today announced that on December 3, 2018, its registration statement on Form F-1, relating to a proposed initial public offering (“IPO” or the “Offering”) of its Class A Ordinary Shares, par value US$1.00 per share (the “Shares”), at a price to the public of $15.80 per share, for gross proceeds of a minimum of US$10 million and up to US$30 million, has been declared effective by the U.S. Securities and Exchange Commission (“SEC”). The Company is offering up to 1,898,734 Shares and up to 51,990 underwriter warrants while certain selling shareholders are offering up to 1,595,235 Shares (collectively, the “Registered Securities”). None of the gross proceeds will be used to purchase the selling shareholders’ securities. The Shares are expected to begin trading on The NASDAQ Global Market on December 18, 2018, under the symbol APM. This Offering is expected to close on or before December 12, 2018, subject to customary closing conditions.… 続きを読む
2018年12月07日
Seattle Genetics和武田呈报 ADCETRIS® (Brentuximab Vedotin)用于表达CD30的外周T细胞淋巴瘤一线治疗3期ECHELON-2临床试验的阳性数据
Seattle Genetics, Inc. (Nasdaq:SGEN)和武田药品工业株式会社(TSE:4502)宣布,3期ECHELON-2临床试验数据将于今天在美国血液学会(ASH)第60届年会上进行口述呈报。该数据显示,ADCETRIS (brentuximab vedotin)联合CHP(环磷酰胺、多柔比星、泼尼松)一线治疗可有效延长无进展生存(PFS)和总生存(OS),安全性接近CHOP(环磷酰胺、多柔比星、长春新碱、泼尼松),CHOP是表达CD30的外周T细胞淋巴瘤(PTCL)患者目前的标准治疗。上述数据同时在《柳叶刀》杂志在线发表。ADCETRIS是一种抗体药物轭合物(ADC),可靶向作用于CD30,若干类型PTCL的表面有CD30表达。… 続きを読む
2018年12月06日
武田の株主がシャイアー買収案に関連した決議事項を承認
本プレスリリースは、その発表、公表または配布が適用法違反となる法域において、全体または一部を問わず、直接または間接的に発表、公表または配布してはなりません。… 続きを読む
2018年12月06日
武田股东批准拟收购Shire plc相关决议
如在任何司法管辖区内直接或间接发布、出版或分发全部或部分内容构成违反该司法管辖区有关法律的行为,则不得在此等司法管辖区实施该行为。… 続きを読む